In the past week, SPRY stock has gone up by 10.95%, with a monthly gain of 11.57% and a quarterly surge of 36.57%. The volatility ratio for the week is 5.07%, and the volatility levels for the last 30 days are 3.87% for ARS Pharmaceuticals Inc The simple moving average for the past 20 days is 8.57% for SPRY’s stock, with a 19.24% simple moving average for the past 200 days.
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
Company’s 36-month beta value is 0.83.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRY is 54.77M, and currently, short sellers hold a 31.29% ratio of that floaft. The average trading volume of SPRY on June 20, 2025 was 1.67M shares.
SPRY) stock’s latest price update
ARS Pharmaceuticals Inc (NASDAQ: SPRY)’s stock price has soared by 7.35 in relation to previous closing price of 14.82. Nevertheless, the company has seen a gain of 10.95% in its stock price over the last five trading days. globenewswire.com reported 2025-05-27 that SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Scotiabank repeating the rating for SPRY by listing it as a “Sector Outperform.” The predicted price for SPRY in the upcoming period, according to Scotiabank is $30 based on the research report published on March 07, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $40. The rating they have provided for SPRY stocks is “Outperform” according to the report published on February 10th, 2025.
SPRY Trading at 12.07% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.05% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from ERIC KARAS, who proposed sale 15,000 shares at the price of $16.00 back on Jun 18 ’25. After this action, ERIC KARAS now owns shares of ARS Pharmaceuticals Inc, valued at $240,000 using the latest closing price.
Fitzpatrick Alexander A, the Chief Legal Officer of ARS Pharmaceuticals Inc, sale 102,969 shares at $14.10 during a trade that took place back on May 20 ’25, which means that Fitzpatrick Alexander A is holding 89,613 shares at $1,451,513 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.91 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -0.16. The total capital return value is set at -0.09. Equity return is now at value -6.91, with -5.64 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -280.6.
Currently, EBITDA for the company is -2.88 million with net debt to EBITDA at 1.47. When we switch over and look at the enterprise to sales, we see a ratio of 15.68. The receivables turnover for the company is 10.44for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.00.
Conclusion
In a nutshell, ARS Pharmaceuticals Inc (SPRY) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
